| Literature DB >> 34680114 |
Agnieszka Gibała1,2, Paulina Żeliszewska2, Tomasz Gosiewski1, Agnieszka Krawczyk1, Dorota Duraczyńska2, Joanna Szaleniec3, Maciej Szaleniec2, Magdalena Oćwieja2.
Abstract
The biocidal properties of silver nanoparticles (AgNPs) prepared with the use of biologically active compounds seem to be especially significant for biological and medical application. Therefore, the aim of this research was to determine and compare the antibacterial and fungicidal properties of fifteen types of AgNPs. The main hypothesis was that the biological activity of AgNPs characterized by comparable size distributions, shapes, and ion release profiles is dependent on the properties of stabilizing agent molecules adsorbed on their surfaces. Escherichia coli and Staphylococcus aureus were selected as models of two types of bacterial cells. Candida albicans was selected for the research as a representative type of eukaryotic microorganism. The conducted studies reveal that larger AgNPs can be more biocidal than smaller ones. It was found that positively charged arginine-stabilized AgNPs (ARGSBAgNPs) were the most biocidal among all studied nanoparticles. The strongest fungicidal properties were detected for negatively charged EGCGAgNPs obtained using (-)-epigallocatechin gallate (EGCG). It was concluded that, by applying a specific stabilizing agent, one can tune the selectivity of AgNP toxicity towards desired pathogens. It was established that E. coli was more sensitive to AgNP exposure than S. aureus regardless of AgNP size and surface properties.Entities:
Keywords: Candida albicans; Escherichia coli; Gram-negative bacteria; Gram-positive bacteria; Staphyloccus aureus; biocidal properties; minimum bactericidal concentration (MBC); minimum inhibitory concentration (MIC); pathogenic fungi; silver nanoparticles; surface properties
Mesh:
Substances:
Year: 2021 PMID: 34680114 PMCID: PMC8533414 DOI: 10.3390/biom11101481
Source DB: PubMed Journal: Biomolecules ISSN: 2218-273X
Types of silver nanoparticles (AgNPs) obtained using selected reagents and described reaction conditions.
| Symbol | Reducing Agent | Stabilizing Agent | T (°C) | pH | Agent for pH Adjustment | Ref. |
|---|---|---|---|---|---|---|
| CHSB1AgNPs | sodium borohydride (SB) | cysteamine hydrochloride (CH) | 20 | 5.2 | - | [ |
| CHSB2AgNPs | sodium borohydride (SB) | cysteamine hydrochloride (CH) | 20 | 5.3 | - | [ |
| CYSSBAgNPs | sodium borohydride (SB) | cysteine (CYS) | 20 | 3.4 | - | [ |
| LYZSBAgNPs | sodium borohydride (SB) | lysine (LYZ) | 20 | 3.7 | - | - |
| ARGSBAgNPs | sodium borohydride (SB) | arginine (ARG) | 20 | 3.4 | - | - |
| TCSBAgNPs | sodium borohydride (SB) | trisodium citrate (TC) | 20 | 7.9 | - | [ |
| TCAgNPs | trisodium citrate (TC) | 88 | 9.1 | - | [ | |
| TCAAAgNPs | ascorbic acid (AA) | trisodium citrate (TC) | 25 | 9.5 | aq. ammonia | - |
| GAAgNPs | gallic acid (GA) | 25 | 8.8 | aq. ammonia | [ | |
| EGCGAgNPs | (−)-epigallocatechin gallate (EGCG) | 25 | 8.9 | aq. ammonia | [ | |
| TAAgNPs | tannic acid (TA) | 25 | 8.5 | aq. ammonia | [ | |
| CFGAAgNPs | gallic acid (GA) | caffeine (CF) | 25 | 8.8 | aq. ammonia | [ |
| GLAgNPs | D-glucose | 25 | 5.3 | aq. ammonia | [ | |
| HHAgNPs | hydroxylamine hydrochloride (HH) | 25 | 10.5 | sodium hydroxide | [ | |
| SHSHAgNPs | sodium hypophosphite (SH) | sodium hexameta-phosphate (SH) | 40 | 2.2 | sulfuric acid | [ |
Blue—AgNPs obtained using sodium borohydride (SB); yellow/orange—AgNPs obtained using trisodium citrate (TC); green—AgNPs obtained using selected antioxidants; grey—AgNPs obtained using glucose; red—AgNPs obtained using selected inorganic compounds.
Figure 1Extinction spectra of diluted AgNP suspensions prepared with the use of (a) sodium borohydride (SB); (b) trisodium citrate (TC); (c) selected antioxidants and glucose (GL); (d) inorganic compounds.
Types of silver nanoparticles (AgNPs) obtained using selected reagents and described reaction conditions.
| Symbol | λmax | PdI | ζ (mV) | ||||
|---|---|---|---|---|---|---|---|
| CHSB1AgNPs | 447 | 55 ± 9 | 0.17 | 1.29 | 50 ± 5 | 4.55 ± 0.12 | 70 ± 2 |
| CHSB2AgNPs | 403 | 12 ± 4 | 0.33 | 5.37 | 12 ± 1 | 3.21 ± 0.17 | 51 ± 2 |
| CYSSBAgNPs | 396 | 12 ± 3 | 0.25 | 5.85 | 11 ± 2 | 2.54 ± 0.28 | 40 ± 4 |
| LYZSBAgNPs | 402 | 16 ± 5 | 0.31 | 4.61 | 14 ± 3 | 1.26 ± 0.09 | 25 ± 2 |
| ARGSBAgNPs | 403 | 13 ± 5 | 0.38 | 4.96 | 13 ± 3 | 1.61 ± 0.06 | 31 ± 2 |
| TCSBAgNPs | 392 | 13 ± 5 | 0.38 | 5.85 | 11 ± 3 | −2.78 ± 0.14 | −45 ± 3 |
| TCAgNPs | 438 | 57 ± 10 | 0.18 | 1.22 | 53 ± 4 | −3.03 ± 0.11 | −47 ± 2 |
| TCAAAgNPs | 400 | 12 ± 4 | 0.33 | 6.44 | 10 ± 2 | −2.53 ± 0.03 | −40 ± 1 |
| GAAgNPs | 397 | 12 ± 4 | 0.33 | 6.44 | 10 ± 3 | 3.29 ± 0.02 | −52 ± 2 |
| EGCGAgNPs | 405 | 15 ± 4 | 0.27 | 4.29 | 15 ± 2 | −3.87 ± 0.06 | −61 ± 1 |
| TAAgNPs | 412 | 13 ± 5 | 0.39 | 5.37 | 12 ± 1 | −3.30 ± 0.23 | −52 ± 3 |
| CFGAAgNPs | 400 | 17 ± 4 | 0.24 | 4.29 | 15 ± 1 | −3.16 ± 0.09 | −49 ± 2 |
| GLAgNPs | 429 | 23 ± 8 | 0.35 | 2.93 | 22 ± 2 | −3.17 ± 0.05 | −50 ± 1 |
| HHAgNPs | 403 | 13 ± 3 | 0.23 | 5.85 | 11 ± 1 | −3.65 ± 0.09 | −55 ± 2 |
| SHSHAgNPs | 398 | 11 ± 3 | 0.27 | 6.44 | 10 ± 2 | −3.76 ± 0.12 | −57 ± 4 |
Blue—AgNPs obtained using sodium borohydride (SB); yellow/orange—AgNPs obtained using trisodium citrate (TC); green—AgNPs obtained using selected antioxidants; grey—AgNPs obtained using glucose; red—AgNPs obtained using selected inorganic compounds.
Biocidal properties of AgNPs expressed as the AgNP concentration established as minimum inhibitory concentration (MIC) and minimum bactericidal concentration (MBC) for a given type of AgNP and determined for E. coli (ATCC 25922), S. aureus (ATCC 292113), and C. albicans (ATCC 10231).
| Symbol |
|
|
| ||||
|---|---|---|---|---|---|---|---|
| MIC | MBC | MIC | MBC | MIC | MBC | ||
| CHSB1AgNPs | 55 ± 9 | 25 | 45 | 45 | 45 | 45 | 45 |
| CHSB2AgNPs | 12 ± 4 | 35 | 75 | 45 | 100 | 20 | 65 |
| CYSSBAgNPs | 12 ± 3 | 45 | 100 | 80 | 100 | 100 | 100 |
| LYZSBAgNPs | 16 ± 5 | 5 | 10 | 5 | 100 | 10 | 60 |
| ARGSBAgNPs | 13 ± 5 | 20 | 30 | 25 | 30 | 25 | 30 |
| TCSBAgNPs | 13 ± 5 | 40 | 45 | 50 | 80 | 100 | 100 |
| TCAgNPs | 57 ± 10 | 15 | 35 | 100 | 100 | 50 | 50 |
| TCAAAgNPs | 12 ± 4 | 25 | 90 | 75 | 100 | 100 | 100 |
| GAAgNPs | 12 ± 4 | 40 | 100 | 40 | 100 | 100 | 100 |
| EGCGAgNPs | 15 ± 4 | 15 | 40 | 30 | 70 | 10 | 10 |
| TAAgNPs | 13 ± 5 | 5 | 15 | 5 | 100 | 80 | 100 |
| CFGAAgNPs | 17 ± 4 | 10 | 60 | 10 | 85 | 30 | 50 |
| GLAgNPs | 23 ± 8 | 25 | 60 | 50 | 100 | 10 | 100 |
| HHAgNPs | 13 ± 3 | 25 | 25 | 100 | 100 | 100 | 100 |
| SHSHAgNPs | 11 ± 3 | 5 | 40 | 15 | 55 | 35 | 100 |
Blue—AgNPs obtained using sodium borohydride (SB); yellow/orange—AgNPs obtained using trisodium citrate (TC); green—AgNPs obtained using selected antioxidants; grey—AgNPs obtained using glucose; red—AgNPs obtained using selected inorganic compounds.
Examples of the biological activity of stabilizing agents applied for the preparation of AgNPs.
| Name of Compound | Examples of Biological Activity of the Compound and Its Derivatives | Ref. |
|---|---|---|
| cysteamine hydrochloride |
Improvement of the bactericidal efficacy of intra-canal medicaments against Induction of apoptosis in cells treated with CH at the level of 10−4–10−3 M | [ |
| L-cysteine |
Enhancement of bactericidal effects of hydrogen peroxide in Inhibition of mycelial growth of the pathogenic fungus affecting grapevines Inhibition and eradication of Amplification of antibiotics activity against the Gram-negative bacteria | [ |
| L-lysine |
Induction of the bactericidal activity of antimicrobial peptides containing repetitive lysine–tryptophan motifs Higher antibacterial efficacy of materials containing poly-l-lysine chains Antimicrobial activity against phytopathogenic Gram-negative bacteria, e.g., the Gram-negative phylum Proteobacteria detected for epsilon-poly-lysine Induction of synergistic antifungal effects by epsilon-poly-lysine combined with chitooligosaccharide and mesoporous silica | [ |
| L-arginine |
Induction of the bactericidal activity of antimicrobial peptides containing repetitive arginine–tryptophan motifs Bactericidal properties by nanolayered materials containing poly-L-arginine Enhancement of bactericidal properties of AgNPs by poly-L-arginine Biological activity towards | [ |
| trisodium citrate |
Inhibition of growth of Gram-negative and Gram-positive bacteria and pathogenic fungi, including Local anticoagulation properties by binding Ca2+ | [ |
| ascorbic acid |
Antibacterial properties towards diverse strains of bacteria Dose-dependent antioxidant and prooxidant properties Modulation of pathogenicity markers of Enhancement of antifungal and antioxidant properties of curcumin | [ |
| gallic acid |
Dose-dependent antioxidant and prooxidant properties Well-established antibacterial, antifungal, and anti-inflammatory properties Inhibition of carcinogenesis in animal models and in vitro cancerous cell lines | [ |
| (−)-epicatechin-3-gallate |
Antibacterial and antiviral properties Documented antifungal properties towards Antioxidant properties Induction of cancer cell apoptosis Neuroprotective properties arising from the inhibition of protein fibrillation processes | [ |
| tannic acid |
Inhibition of bacteria growth and suppression of the mutagenesis in Antifungal properties against Antioxidant properties and ability to scavenge free radicals Antiamylogenic activity and possibilities to destabilize abnormal protein fibrils | [ |
| caffeine |
Widely described antibacterial and antifungal properties Antiviral properties towards selected viruses Dose-dependent antioxidant and pro-oxidant properties | [ |
| hydroxylamine mine hydrochloride |
A strong mutagen with reported activity against phages, viruses, bacteria, fungi, protozoa, and plants | [ |
| sodium hexametaphosphate |
Inorganic permeabilizer increasing the permeability of biological membranes Enhancer of bactericidal properties of other biologically active substances | [ |